Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients – PART 1: Risk Factors, Clinical Impact and Immune Response
Reviews in Medical Virology · 2026
DOI: 10.1002/rmv.70142 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reviews in Medical Virology, 2026. Verfasst von Danya Kaplan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Infection, Immunity, and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales,…. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Cytomegalovirus, Immunotherapy, Adoptive. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Human cytomegalovirus (HCMV) is one of the most important opportunistic pathogens in immunocompromised individuals, including allogeneic haematopoietic stem cell transplant (allo‐HSCT) recipients. In allo‐HSCT, HCMV seropositivity of the recipient and donor is associated with inferior survival outcomes, and post‐transplant HCMV reactivation is a frequent complication, necessitating close viral monitoring and pre‐emptive and prophylactic antiviral therapies. We present a review in two parts that focuses on the risk factors, immunological responses and treatment strategies for HCMV infection in allo‐HSCT recipients, and also explores current evidence surrounding HCMV reactivation in recipients of chimeric antigen receptor T cell (CAR T) therapies. In the current article (Part 1), the impact of HCMV infection in allo‐HSCT and CAR T cell recipients is investigated. HCMV reactivation in allo‐HSCT recipients is associated with increased mortality, graft‐versus‐host disease (GvHD) and other microbial infections. Prominent alterations in T cell and natural killer (NK) cell recovery represent distinct immune reconstitution features associated with HCMV reactivation. Immunological biomarkers to predict HCMV complications have been proposed and their adoption in future immune monitoring strategies may allow individualised risk assessment to guide antiviral treatment decisions. The clinical significance of HCMV reactivation after CAR T cell infusion is yet to be fully determined. Continued viral surveillance and investigation of viral dynamics with correlative studies of immune function are needed in this patient population. Current and emerging strategies for treatment and prevention of HCMV complications in allo‐HSCT, including use of letermovir prophylaxis and adoptive HCMV‐specific T cell therapies, are explored in the following article (Part 2).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infection, Immunity, and Inflammation, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
- Charles Perkins Centre, the Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, New South Wales, Australia.
- Westmead Institute for Medical Research, Westmead, New South Wales, Australia.
- Department of Haematology Westmead Hospital, Blood Transplant and Cell Therapies Program, Sydney, New South Wales, Australia.
- Faculty of Medicine and Health, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
- Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
ORCID-Profile: Danya Kaplan, Emily Blyth, Gaurav Sutrave, Michelle K Yong, David J Gottlieb, Barry Slobedman, Lauren Stern
Zitieren
APA
Kaplan, D., Blyth, E., Sutrave, G., Yong, M. K., Gottlieb, D. J., Abendroth, A., Slobedman, B., & Stern, L. (2026). Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients – PART 1: Risk Factors, Clinical Impact and Immune Response. Reviews in Medical Virology. https://doi.org/10.1002/rmv.70142
Vancouver
Kaplan D, Blyth E, Sutrave G, Yong MK, Gottlieb DJ, Abendroth A, et al. Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients – PART 1: Risk Factors, Clinical Impact and Immune Response. Reviews in Medical Virology. 2026. doi:10.1002/rmv.70142
BibTeX
@article{Kaplan2026,
author = {Kaplan, Danya and Blyth, Emily and Sutrave, Gaurav and Yong, Michelle K and Gottlieb, David J and Abendroth, Allison and Slobedman, Barry and Stern, Lauren},
title = {Human Cytomegalovirus Infection in Haematopoietic Stem Cell Transplant Recipients and CAR T Cell Recipients – PART 1: Risk Factors, Clinical Impact and Immune Response},
journal = {Reviews in Medical Virology},
year = {2026},
doi = {10.1002/rmv.70142}
}
EUVIMED